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Abstract
Background: Infectivity of retroviruses such as HIV-1 and MuLV can be abrogated by compounds targeting zinc
finger motif in viral nucleocapsid protein (NC), involved in controlling the processivity of reverse transcription and
virus infectivity. Although a member of a different viral family (Pneumoviridae), respiratory syncytial virus (RSV)
contains a zinc finger protein M2-1 also involved in control of viral polymerase processivity. Given the functional
similarity between the two proteins, it was possible that zinc finger-reactive compounds inactivating retroviruses
would have a similar effect against RSV by targeting RSV M2-1 protein. Moreover, inactivation of RSV through
modification of an internal protein could yield a safer whole virus vaccine than that produced by RSV inactivation
with formalin which modifies surface proteins.
Results: Three compounds were evaluated for their ability to reduce RSV infectivity: 2,2’-dithiodipyridine (AT-2),
tetraethylthiuram disulfide and tetramethylthiuram disulfide. All three were capable of inactivating RSV, with AT-2
being the most potent. The mechanism of action of AT-2 was analyzed and it was found that AT-2 treatment
indeed results in the modification of RSV M2-1. Altered intramolecular disulfide bond formation in M2-1 protein of
AT-2-treated RSV virions might have been responsible for abrogation of RSV infectivity. AT-2-inactivated RSV was
found to be moderately immunogenic in the cotton rats S.hispidus and did not cause a vaccine-enhancement seen
in animals vaccinated with formalin-inactivated RSV. Increasing immunogenicity of AT-2-inactivated RSV by adjuvant
(Ribi), however, led to vaccine-enhanced disease.
Conclusions: This work presents evidence that compounds that inactivate retroviruses by targeting the zinc finger
motif in their nucleocapsid proteins are also effective against RSV. AT-2-inactivated RSV vaccine is not strongly
immunogenic in the absence of adjuvants. In the adjuvanted form, however, vaccine induces immunopathologic
response. The mere preservation of surface antigens of RSV, therefore may not be sufficient to produce a highly-
efficacious inactivated virus vaccine that does not lead to an atypical disease.
Background
Vaccines for numerous infectious diseases have been
developed using whole inactivated virions. Some of the
successful examples include inactivated hepatitis A vac-
cine [1], poliovirus vaccine [2], and SIV vaccine [3].
While providing effective protection in some cases, inac-
tivated virus vaccines are sometimes associated with the
exacerbation of the disease. For example, formalin-inac-
tivated respiratory syncytial virus (RSV) vaccine admi-
nistered to infants and children in the United States in
the 1960’s resulted in the enhancement of the disease
after subsequent exposure of these children to RSV [4].
Similarly, formalin-inactivated measles vaccine, also
developed in the 1960’s, caused a severe and atypical
form of measles following exposure to the wild type
measles virus [5]. While the exact cause of such atypical
responses to formalin-inacti v a t e dv i r u s e si sn o tk n o w n ,
one possible explanation is that traditional means of
viral inactivation, such as formalin or heat treatment
can denature virion surface proteins [6]. This would
result in altered antigenicity of a virus, accompanied by
an atypical and often harmful host response to infection.
Viral inactivation with maximal preservation of its origi-
nal structure may thus provide a solution for successful
vaccine development against diseases currently refrac-
tory to vaccination.
In the past, one particularly interesting method for
such “preserving” viral inactivation has been developed. * Correspondence: marinab@virionsystems.com
Virion Systems, Inc. 9610 Medical Center Drive, Suite 100, Rockville, MD, USA
Boukhvalova et al. Virology Journal 2010, 7:20
http://www.virologyj.com/content/7/1/20
© 2010 Boukhvalova et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.The target of this method have been nucleocapsid (NC)
proteins of retroviruses, such as a human immunodefi-
ciency virus 1 (HIV-1), murine leukemia virus (MuLV)
and simian immunodeficiency virus (SIV). The nucleo-
capsid proteins of these viruses are small basic proteins
that bind single-stranded nucleic acids and increase
synthesis of full length DNA during the reverse tran-
scription reaction. All retroviral NC proteins (with an
exception of spumaretrovirus group [7]) contain one or
two copies of a zinc finger motif. This zinc finger motif
is essential for viral replication, as mutations in the
zinc-coordinating residues lead to the loss of infectivity
and significant reduction of genomic RNA packaging
[8-10]. The exact mechanism by which the NC protein
operates is not known, but it is thought that the NC
protein acts as a nucleic acid chaperone that facilitates
initiation of reverse transcription and serves to reduce
pausing by the reverse transcriptase to ensure efficient
synthesis of full-length DNA during virus replication
[11,12]. Moreover, residues within and flanking the zinc
finger in the NC protein are responsible for processivity
of reverse transcription reaction [12]. The conserved
nature of the zinc finger motifs, as well as its crucial
role in a viral life cycle, made NC proteins an attractive
target for development of antiretroviral drugs. In parti-
cular, several compounds have been identified that cova-
lently modify the NC zinc fingers resulting in ejection of
Zn
2+ and loss of infectivity [13-15]. Detailed analysis of
HIV-1 inactivation by one of such compounds, namely
aldrithiol-2 (AT-2) has been studied in considerable
detail and revealed that while the viral infectivity was
abrogated, virions were able to enter the target cells and
the virion surface proteins retained structural and func-
tional integrity [16].
A number of reasons prompted us to believe that a
similar approach for virus inactivation can be applied to
the respiratory syncytial virus (RSV). RSV is a member
of the genus Pneumovirus that contains a negative-
strand RNA genome encoding 11 proteins. One of these
proteins, M2-1, contains a zinc finger motif. This pro-
tein apparently serves the same role in RSV as the
nucleocapsid protein does in retroviruses: it controls
processivity of viral polymerase. In particular, M2-1 pre-
vents premature termination during transcription of the
viral mRNAs [17,18]. M2-1 is a 22 kDa protein encoded
by the first (upstream) ORF of M2 mRNA. The zinc fin-
ger motif is located in the N-terminus of the protein,
from residues 7 to 25. Just as retroviral NC proteins are
important for retroviruses, M2-1 is required for RSV to
produce infectious particles [19]. Moreover, the intact
zinc finger motif of the M2-1 protein is required for
maintaining functional integrity of the protein [20]. The
zinc finger motifs of RSV M2-1 protein and NC proteins
of retroviruses have slightly different consensus
sequences: C-X7-C-X5-C-X3-H (so-called Cys3-His1
motif) for M2-1 protein and C-X2-C-X4-H-X4-C (CCHC
motif) for NC proteins, where X denotes variable amino
acids [21,22]. The Cys3-His1 motif is found in M2-1
proteins of all the pneumoviruses examined up to date
[20]. This motif is also present in the human zinc-bind-
ing protein, Nup475, involved in regulation of mRNA
stability [23,24]. The structure of the Nup475 Cys3-His1
motif has been proposed based on nuclear magnetic
resonance and photometric analysis, revealing that the
Zn
2+ ion is coordinated by three conserved cystein resi-
dues and one histidine residue in the Cys3-His1 motif
[23,25]. Although the sequence of the zinc finger CCHC
motif of NC proteins differs from that of the Cys3-His1
motif, Zn
2+ ions bind to the CCHC motifs also through
coordination with the three cystein and one histidine
residues [21,22]. Thus, in spite of the difference in the
length of the loops connecting Zn-coordinating residues,
Zn
2+ ions appear to bind in a similar manner to both
Cys3-His1 and CCHC motifs.
Given the functional similarity between the zinc finger
containing proteins of retroviruses and RSV, and simi-
larity in basic architecture of the zinc finger motifs in
these proteins, we have noted a possibility that some of
the chemicals identified as reactive towards the zinc fin-
ger motif in the NC proteins might also react with the
zinc finger motif of the M2-1 protein of RSV. Therefore,
we have tested some of the zinc finger reactive com-
pounds that were discovered as active against HIV-1
and MuLV in the experiments using respiratory syncy-
tial virus. This paper reports that the zinc finger reactive
compounds capable of inactivating HIV-1 and other ret-
roviruses by targeting their nucleocapsid protein are
also capable of inhibiting RSV infectivity, and that this
inhibition is accompanied by modification of the RSV
zinc finger containing protein M2-1. This type of inacti-
vation might allow maximum preservation of the virion
surface structure, a feature important in view of future
vaccine development.
Results
Zinc-finger-reactive compounds are effective against RSV
as measured by their effect on infectivity
Three compounds were chosen for evaluation of their
effect on RSV infectivity: 2,2’-dithiodipyridine
(aldrithiol-2; hereafter referred to as AT-2), tetra-
ethylthiuram disulfide and tetramethylthiuram disulfide.
These chemicals were previously demonstrated to inacti-
vate HIV-1 and MuLV through targeting their nucleo-
capsid zinc finger proteins [13,15,16]. The effect of AT-
2, tetraethylthiuram disulfide and tetramethylthiuram
disulfide on the infectivity of RSV was tested by incubat-
ing RSV with each one of these chemicals and then
assessing remaining RSV infectivity on HEp-2 cells. All
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AT-2 being the most potent inhibitor (Figure 1). At the
concentration of 10 mM, AT-2 decreases RSV infectivity
to below the detection level (10 pfu/ml). Tetra-
ethylthiuram disulfide and tetramethylthiuram disulfide,
while significantly reducing infectivity of RSV, were not
as effective as AT-2 at similar concentration. The effect
of higher concentrations of these two chemicals on RSV
infectivity, however, was impossible to test due to their
limited solubility (data not shown).
Infectivity of AT-2-inactivated RSV was also assessed
in vivo using cotton rats (Figure 2). Animals were intra-
nasally inoculated with RSV inactivated by 10 mM AT-2
for 24 hrs, or sham-treated for 24 hrs. Four days later,
animals were sacrificed and viral replication in the lungs
evaluated. No infectious viral particles were detected in
the lungs of animals inoculated with AT-2-inactivated
RSV, while sham-treated RSV replicated efficiently in
the lungs of infected animals (Figure 2).
Dynamics of RSV inactivation by AT-2
Effect of AT-2 on RSV infectivity was investigated in
more detail following the initial observation that AT-2
was the compound most effective at inhibiting RSV (Fig-
ure 3). First, the time-dependency of RSV inactivation
by AT-2 was explored. Inactivation reactions containing
10 mM or 30 mM AT-2 were set up and allowed to
proceed for 2, 6, 24 or 48 hours. In the absence of AT-2
treatment, sucrose-stabilized RSV was rather stable (Fig-
ure 3A), consistent with earlier observations using a
similarly prepared and stabilized RSV [26]. Incubation of
this virus for as long as 48 hrs at 37°C diminished RSV
infectivity by less than one Log10 pfu/ml. When RSV was incubated in the presence of AT-2, however, inacti-
vation of virus was visible within the first 2 hours of
incubation. In that time period, RSV infectivity dimin-
ished by 2 or 3 Log10 pfu/ml when 10 mM and 30 mM
AT-2 were used, respectively. 24 hour incubation with
AT-2 resulted in no detectable infectious viral particles
left. Inactivation of RSV by AT-2 did not appear to fol-
low single-hit kinetics, in contrast to RSV inactivation
by irradiation with ultraviolet light [27]. 30 mM AT-2,
while producing higher inactivation of RSV at 2 hrs, did
not significantly increase RSV inactivation compared to
the lower, 10 mM AT-2 concentration, probably due to
the fact that solubility of AT-2 at 30 mM was already
limited (data not shown). Twenty four hour inactivation
period, therefore, was identified as the one sufficient for
complete inactivation of RSV by concentrations of AT-2
equal to or higher than 10 mM. The dose-dependence
of inactivation was determined next by incubating RSV
with various amounts of AT-2 for 24 hrs (Figure 3B).
AT-2 in the concentration of 5 mM or higher dimin-
ished RSV infectivity to below the detection level. At the
lowest dose tested, 100 nM AT-2, RSV infectivity was
reduced by over 1.5 Log10 pfu/ml.
Figure 1 Inactivation of respiratory syncytial virus by AT-2,
Tetramethylthiuram disulfide, and Tetraethylthiuram disulfide.
RSV was treated with 10 mM of the indicated compounds for 24
hrs at 37°C. Viral titers were then determined by plaque assay on
HEp-2 cells. Control reactions (corresponding to “0m M ” of each
chemical) contained the same amount of DMSO as that present in
drug-containing incubations.
Figure 2 Inability of respiratory syncytial virus inactivated with
AT-2 to replicate in the lungs of cotton rats. RSV was inactivated
by incubation with 10 mM AT-2 for 24 hrs at 37°C. Virus was then
diluted with PBS and used to intranasally infect cotton rats. Control
animals received sham-treated RSV. Four days post-challenge
animals were sacrificed and lungs were collected for viral titrations.
Results shown are the mean log (viral titer) ± SE for 4 animals per
group.
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RSV M2-1 protein
Several research groups have demonstrated that zinc fin-
ger reactive compounds that inactivate retroviruses do
so by targeting their zinc finger motif containing
nucleocapsid proteins. These compounds were shown to
penetrate the viral envelope of cell-free HIV-1 and
MuLV and react with nucleocapsid protein of these
viruses [14,15,28], causing formation of intra- and inter-
molecular disulfide crosslinks. As M2-1 is the only pro-
tein of RSV containing a zinc finger motif, and the most
likely target of the AT-2 action, we set to determine
whether a similar modification of the M2-1 protein
occurs following AT-2 treatment of cell-free RSV. To
address that question, AT-2 treated RSV particles were
lysed and fractionated by sodium dodecyl sulfate-polya-
crylamide gel electrophoresis (SDS-PAGE) either in the
presence or in the absence of b-ME. The proteins were
then analyzed by Western blot using IgY antibodies
against RSV antigens (Figure 4).
M2-1 protein in RSV-infected cells has been reported
to migrate as multiple species. This variability is due in
part to the formation of intramolecular disulfide bonds
[29], as well as to the existence of the phosphorylated
form of M2-1 protein [20]. Less is known about electro-
phoretic behavior of M2-1 protein present in cell-free
RSV virions. In the presence of b-ME we detected a sin-
gle band corresponding to M2-1 protein in untreated
RSV virions, designated as the band “a” in Figure 4A
(lane 3). This band migrates with an apparent molecular
weight of ~26-27 kDa and corresponds in size to the
m a i nM 2 - 1b a n dd e t e c t e dw i t ht h es a m ea n t i b o d yi n
RSV-infected HEp-2 and A549 cells (data not shown).
In the absence of b-ME, however, several M2-1 bands
are visible in cell-free RSV (bands “b”, “d”,a n d“c” in
Figure 4A, lane 1). Band “b” contained the majority of
M2-1 molecules and based on its apparent molecular
weight corresponds to the monomeric form of M2-1
protein. Bands “c” and “d”, although barely visible, most
likely represent a dimer of M2-1 stabilized by intermole-
cular disulfide crosslinks, as these bands disappeared in
the presence of b-ME (compare lane 1 to lane 3). M2-1
protein of RSV in the absence of b-ME (band “b”,l a n e
1) has a slightly better electrophoretic mobility than in
the presence of b-ME (band “a”, lane 2), suggesting that
it might be a conformational form stabilized by intramo-
lecular disulfide bonds.
In the presence of b-ME, M2-1 protein of virions trea-
ted with AT-2 had the same electrophoretic mobility as
M2-1 protein of untreated, control virus (Figure 4A,
c o m p a r el a n e4t ol a n e3 ) .I nt h ea b s e n c eo fb-ME,
however, electrophorectic mobility of M2-1 was signifi-
cantly different. AT-2 treatment had converted a sub-
stantial fraction of the M2-1 protein into a higher-
molecular-weight band of approximately 46 kDa, evi-
dently a dimer of M2-1 protein (band “c”,l a n e2 ) .T h e
disappearance of this band following b-ME treatment
also suggests that it might be disulfide-bond crosslinked
dimer of M2-1. Moreover, a band corresponding to a
monomer of M2-1 protein in untreated RSV virions
(band “b”) had shifted to a slightly higher position fol-
lowing AT-2 treatment, acquiring electrophoretic mobi-
lity similar to that of reduced M2-1 protein species in
both untreated RSV and in virions treated with AT-2
(band “a”). Assuming that the band “b” in untreated
RSV virions represents a M2-1 form stabilized by intra-
molecular disulfide bonds, the disappearance of this
Figure 3 Time- and dose-dependence of RSV inactivation by
AT-2. (A) Time course of RSV inactivation. RSV was incubated with
10 mM, 30 mM AT-2 or the corresponding amount of DMSO
(control, no AT-2) at 37°C for different times. At the indicated time
points, reaction was stopped and viral infectivity was determined by
plaque assay on HEp-2 cells. Dashed line indicates the limit of the
sensitivity of titration assay. (B) Dose response curve of RSV
inactivation by AT-2. RSV was incubated with the indicated amounts
of AT-2 at 37°C for 24 hrs. Viral titers were determined by plaque
assay on HEp-2 cells. Dashed line indicates the limit of the
sensitivity of titration assay.
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cystein residues previously involved in formation of
these disulfide bonds.
To determine whether AT-2 treatment in addition to
modifying M2-1 protein might have caused a modifica-
tion of other RSV proteins, we have used chicken IgY
antibodies to several RSV proteins in immunoblots of
fractionated treated/untreated virions. Figures 4B and
4C show representative immunoblots of RSV P and N
proteins, respectively. It can be seen that neither P, nor
N protein appear to be modified by AT-2 treatment of
RSV, as evidenced by similar electrophoretic behavior of
these proteins both in AT-2-treated and in control pre-
paration under reducing or non-reducing conditions.
Similarly, no modification of RSV F or G proteins was
detected following AT-2 treatment (data not shown).
Moreover, treatment of RSV with AT-2 has not appar-
ently affected the total amount of virus following inacti-
vation, as comparable levels of structural RSV proteins
were detected in both AT-2-treated and control,
untreated RSV preparations.
Immunogenicity of AT-2-inactivated RSV
Modification of surface proteins during inactivation of
RSV by formalin is thought to contribute to the devel-
opment of an atypical enhanced disease during subse-
quent RSV infection [6]. AT-2 targets an internal viral
protein while preserving surface proteins and may there-
fore generate a safer RSV vaccine. To test this hypoth-
esis, we have addressed efficacy and safety of AT-2-
inactivated RSV in the cotton rat S.hispidus model
Figure 4 Respiratory syncytial virus inactivation by AT-2 is accompanied by modification of the M2-1 protein. RSV was inactivated by
incubation with 10 mM AT-2 for 24 hrs at 37°C (lanes 2 and 4), or with corresponding amount of DMSO (lanes 1 and 3). At the end of the
incubation, RSV particles were lysed and analyzed by SDS-PAGE either in the presence (lanes 3 and 4), or in the absence (lanes 1 and 2) of b-ME,
followed by immunoblotting with IgY against RSV: (A) M2-1 protein, (B) P protein, and (C) N protein.
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(RSV/AT-2) was compared to that of formalin-inacti-
vated RSV (FI-RSV) and to immunity induced by repeat
live RSV infection (live RSV). When administered in the
absence of any adjuvants, AT-2 inactivated RSV con-
ferred a moderate but statistically-significant reduction
of RSV load in the lung (Figure 5A). The extend of this
reduction was comparable to that caused by FI-RSV,
however no histopathological response associated with
formalin-inactivated virus was seen with AT-2-inacti-
vated RSV (Figure 5B). To improve immunogenicity of
AT-2-inactivated RSV, Ribi adjuvant was included into
vaccine formulation. The resulting vaccine (adjRSV/AT-
2) afforded complete protection of the lung from RSV
replication (Figure 5A), but also caused a vaccine-
enhanced disease (Figure 5B).
Discussion
Human Respiratory Syncytial Virus is a member of the
Pneumovirus genus of the family Paramyxoviridae.
Replication of paramyxoviruses is a complex process
that relies on transcription of virally-encoded proteins
tightly linked to replication of viral genome through the
synthesis of antigenome intermediate. The RNA poly-
merase complex involved in transcription and replica-
tion of RSV genome consists of the N, P and L proteins
[30,31], but requires an additional protein, M2-1, to
ensure efficient transcription and replication.
M2-1 is a 194 amino acid protein required for synth-
esis of RSV RNA. This protein is an antitermination fac-
tor that increases processivity of viral RNA polymerase
at gene junctions and prevents premature termination
during transcription [17,18,20,32]. M2-1 protein in RSV-
infected cells can exist in a phosphorylated form, and is
capable of binding to the nucleocapsid protein of RSV
[20]. The importance of both of these features for the
function of M2-1 protein is currently unknown. The N-
terminal part of the M2-1 protein contains a Cys3-His1
motif (C-X7-C-X5-C-X3-H). This motif is present in all
currently known pneumoviruses [33]. A similar motif is
present in mammalian transcription factor Nup475,
where it was shown to bind zinc [23]. The Cys3-His1
Figure 5 Immunogenicity of AT-2-inactivated RSV in the cotton rat model.C o t t o nr a t sw e r ei m m u n i z e dintramuscularly with AT-2-
inactivated RSV ("RSV/AT-2”), AT-2-inactivated RSV adjuvanted with Ribi emulsion (adjRSV/AT-2) or formalin-inactivated RSV (FI-RSV). Control
animals remained unvaccinated ("control”) or were immunized via repeated infection with live RSV ("live RSV”). All animals were challenged with
RSV and sacrificed 4 days after infection for analysis of pulmonary viral load (A) and histopathology (B). Results are the mean ± SEM for 4
animals per group. *p < 0.05 when compared to the “control” group.
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mutations at some of the predicted zinc-coordinating
residues prevent M2-1 from enhancing transcriptional
read-through, alter M2-1 phosphorylation state and pre-
vent M2-1 interaction with the nucleocapsid protein in
transfected cells [20,34].
The Cys3-His1 motif of the RSV M2-1 protein differs
in consensus sequence from the conserved CCHC zinc
finger motif of retroviral nucleocapsid proteins. Yet, the
M2-1 protein of human respiratory syncytial virus dis-
plays functional similarity to the nucleocapsid protein of
retroviruses such as HIV-1 and MuLV: both proteins
control processivity of viral polymerase, both are
required to produce infectious viral particles, and both
are functionally dependent on intact zinc finger motif.
This paper presents evidence that compounds that inac-
tivate retroviruses by targeting the zinc finger motif in
their nucleocapsid proteins are also effective against
human respiratory syncytial virus. A detailed analysis of
the effect of one of such compounds, namely, AT-2 on
RSV infectivity is described, and it reveals that RSV
inactivation by AT-2 in accompanied by modification of
the M2-1 protein. The fact that a compound acting by
covalently modifying zinc finger motif containing pro-
teins of retroviruses can inactivate a pneumovirus
through targeting a zinc finger motif containing protein
of seemingly analogous function, suggests that mechan-
isms of viral transcription and replication might be
more conserved than currently appreciated, and might
point to an evolutionary link between viruses of genus
Pneumovirus and some retroviruses. Significant inactiva-
tion of RSV by AT-2, however, required extending the
inactivation time to as long as 24 hours. While such a
prolonged incubation does not dramatically affect infec-
tivity of control sucrose-stabilized RSV preparation, it
might not be an acceptable approach for un-stabilized
RSV that is heat-labile [26]. Chemicals other than AT-2,
but with similar mode of action might be more effective
in inactivating RSV faster. Zinc finger reactive com-
pounds inhibiting HIV-1 infectivity have been identified
by the National Cancer Institute’s drug screening pro-
gram [14]. A similar type of approach might be needed
to identify compounds that target more efficiently the
zinc finger motif of RSV and other pneumoviruses.
Numerous methods of inactivation of respiratory syn-
cytial virus have been attempted in the quest for a safe
and efficient RSV vaccine. Each one of them, however,
has been plagued by its own limitations. Chemical meth-
ods of RSV inactivation, such as formalin treatment,
have led to unexpected enhancement of pulmonary dis-
ease in vaccines that have acquired natural RSV infec-
tion following vaccination [4,5]. Subunit RSV vaccines
often lack sufficient antigenicity, while development of
attenuated replicating RSV vaccines has been
complicated by their residual virulence and genetic
instability [35-37]. The method of chemical inactivation
of respiratory syncytial virus described here carries at
least two advantages when compared to other methods
of RSV inactivation. First, a large scale production of
RSV inactivated by means of chemical targeting its M2-
1 protein is easily attainable, as a viral pool of replica-
tion-competent virus is grown prior to its inactivation.
This contrasts with the complication associated with the
live attenuated RSV vaccine candidates, which are often
less efficient in replication. Second, a chemical used for
inactivation (AT-2 in this case) penetrates the viral
envelope and targets a viral protein that is located inside
the viral particle, rather than proteins located on its sur-
face. This type of inactivation might spare surface-
exposed molecules often serving as antigenicity determi-
nants. In fact, the harmful effect of formalin-inactivated
RSV vaccine is believed to be associated with the
adverse modification of surface RSV proteins following
formalin treatment [6]. Our results show that AT-2-
inactivated RSV is immunogenic and that at the doses
affording protection comparable to protection induced
by FI-RSV vaccine it does not cause a vaccine-enhanced
disease. These results support the hypothesis that modi-
fication of surface antigens by formalin may be contri-
buting to the development of an atypical disease [6].
The potential contribution of alum contained in FI-RSV
but not RSV/AT-2 vaccine to a development of vaccine-
enhanced disease, however, cannot be ruled out [38].
This work also demonstrates that AT-2-inactivated RSV
is only moderately immunogenic and that inclusion of
an adjuvant is needed to improve its efficacy. This is not
surprising as most subunit and inactivated RSV vaccines
generated so far and administered parenterally do not
induce a robust immune response in the absence of an
adjuvant [39]. Increasing immunogenicity of AT-2-inac-
tivated RSV also increases the potential of this vaccine
to cause vaccine-enhanced disease, suggesting that pre-
servation of surface antigenic determinates of inactivated
RSV is not sufficient to create a highly efficacious and
safe whole virus vaccine against RSV disease.
Respiratory syncytial virus inactivated by an approach
described in this paper might present a valuable tool for
investigation into the mechanisms of RSV action. Patho-
genesis of respiratory syncytial virus infection depends
in large part on host immune and inflammatory
response to the virus. Events triggered by the initial con-
tact of the virus with cells of the innate immune system
might ultimately be responsible for the outcome of the
infection. Targeted inactivation of RSV with possible
preservation of the majority of structural proteins, com-
bined with the ease of production of such inactivated
viral particles, might help to advance our understanding
of RSV biology.
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This work demonstrates that compounds inactivating
retroviruses through targeting their zinc finger-contain-
ing NC proteins can also inactivate RSV. Inactivation of
RSV by AT-2 is accompanied by a significant modifica-
tion of RSV M2-1, a change that is likely contributing to
the loss of viral infectivity. Inactivated virus in the
absence of adjuvants is moderately immunogenic and
does not cause a vaccine-enhanced disease in contrast
to formalin-inactivated RSV. Addition of Ribi adjuvant
dramatically increases immunogenicity of AT-2-inacti-
vated RSV, but also leads to enhanced pulmonary
pathology, limiting the vaccine potential of RSV inacti-
vated with zinc-finger-reactive compounds. AT-2 inacti-
vated RS, however, may present an important research
tool for understanding immunobiology of RSV disease.
Methods
Viruses and Cells
Long strain of RSV was obtained from American Type
Culture Collection, Manassas, VA and propagated in
HEp-2 cells after serial plaque purification. A pool of
virus containing 10
7.5 pfu/ml in stabilizing media com-
posed of 25% sucrose and 2% FBS in PBS, pH 7.4 [26]
was used for all experiments. Viral titers were deter-
mined by plaque assay using HEp-2 cells as described in
Prince et al., 1978 [40].
Chemicals and Antibodies
Aldrithiol-2 (AT-2), Tetraethylthiuram disulfide and
Tetramethylthiuram disulfide were purchased from
Sigma-Aldrich. AT-2 was reconstituted in 100% DMSO
to a stock concentration of 300 mM. Tetraethylthiuram
disulfide and tetramethylthiuram disulfide were reconsti-
tuted at 169 mM and 208 mM, respectively, using
DMSO as a solvent as well. Unless otherwise stated,
further dilutions of chemicals were done in PBS, pH 7.4.
Chicken IgY antibodies against various RSV proteins
were kindly provided by Robert Brazas (currently at
Epigenetics).
Vaccines and Adjuvants
FI-RSV vaccine Lot 100 was kindly provided by Dr.
Hyun-Wha Kim, one of the participants in the clinical
trials in 1965-1967 [4]. FI-RSV preparation contained
alum and has been maintained under refrigeration since
the time of its manufacture. Ribi adjuvant (MPL, TDM,
CWS Emulsion) was purchased from Sigma-Aldrich.
Chemical RSV inactivation
Frozen virus stocks were thawed at 37°C in a water
bath. Inactivation reactions were carried in 200 μlt o t a l
volume, using PBS, pH 7.4 as a buffer. Each reaction
contained 20 μlo f1 0
7.5 pfu/ml RSV Long, and appro-
priate amount of chemical stock to yield the working
concentration of 1-30 mM. Control reactions contained
amount of DMSO equal to that present in the drug-
containing incubations (up to 10% DMSO). Reactions
were incubated in 37°C air-incubator with constant
shaking at 225 rpm for 2-24 hrs and vortexed every 2
hrs during the first 8 hrs to disaggregate the virus. At
the end of the incubation period, virus was concentrated
and chemicals were removed by ultrafiltration against
PBS, pH 7.4 using Centricon YM-100 columns (Milli-
pore). Samples were then snap-frozen on dry ice and
stored at -70°C.
Animal experiments
A d u l ti n b r e dc o t t o nr a t s( S. hispidus) were obtained
from the colony maintained at Virion Systems, Inc.
(Rockville, MD). Animals were fed a standard diet of
rodent chow and water and housed in large polycarbo-
nate cages. For the assessment of AT-2-inactivated-RSV
ability for pulmonary replication, two groups of animals
(four animals each) were used. RSV was inactivated by
incubation with 10 mM AT-2 for 24 hrs at 37°C as out-
lined above. Control virus preparation was incubated in
parallel with AT-2-containing reaction, but in the
absence of AT-2. Animals were inoculated intranasally
under isoflurane anesthesia with 100 μl/animal of sham-
treated RSV or with 100 μl/animal of the AT-2-inacti-
vated RSV, both originally containing 10
5 pfu RSV
Long. On day 4 post-challenge animals were killed by
carbon dioxide intoxication. Lungs were extracted and
homogenized for virus quantification.
Immunogenicity of AT-2-inactivated RSV was tested
via parenteral route. Groups of 4-5 S.hispidus were
inoculated intramuscularly (thigh) under isoflurane
anesthesia with 100 μl of AT-2-inactivated virus (with
or without 75 μg Ribi adjuvant), containing an equiva-
lent of 5.5*10
3 pfu of RSV Long. FI-RSV-vaccinated ani-
mals received i.m. injection of FI-RSV diluted 1:125 in
PBS, pH 7.4. Animals were boosted on day 21 after
immunization with the same formulation as used for
priming, and on day 42 after the initial immunization
challenged with RSV Long, 3*10
5 pfu in 100 μlp e ra n i -
mal. Four days after infection all animals were sacrificed
by CO2 inhalation, lungs removed and bisected for viral
titers and histopathology analyses. Live infection-immu-
nized animals were challenged with RSV Long, 3*10
5
pfu in 100 μl per animal twice with an interval of 21
days and sacrificed 4 days after the second challenge.
Histolopathology was analyzed as previously described
[41]. In brief, lungs were intratracheally inflated with
10% neutral buffered formalin, embedded in paraffin,
and sectioned at 4 μM. Sections were stained with hae-
matoxylin and eosin (HistoServe, Gaithersburg, MD).
Each lung section was scored for one of the four para-
meters of pulmonary inflammatory changes: peribronch-
iolitis (inflammatory cells, primarily lymphocytes,
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within the bronchial epithelium), alveolitis (inflamma-
tory cells within alveolar spaces) and interstitial pneu-
monitis (increased thickness of alveolar walls associated
with inflammatory cells [41]. Each parameter was scored
individually for each section. Maximum possible value
for each lesion was 4. Viral titers were determined by
plaque assay [40] and expressed as geometric mean ±
SE values for all cotton rats in a group. Student’stt e s t
was used to evaluate differences among groups. Histolo-
gical lesion scores were also expressed as mean ± SE
values for all cotton rats in a group.
Analysis of RSV proteins by Western blotting
Virus inactivations for Western blot analysis were car-
ried in 2 ml total volume, and otherwise were analogous
to 200 μl inactivation reactions outlined above. Suspen-
sion of inactivated/control virus corresponding to 10
7.5
pfu/ml virion particles (as determined for control reac-
tion, in which no inactivating agent was present) was
diluted 1:2.5 with PBS, pH 7.4, after what 2× SDS-load-
ing buffer with or without b-mercaptoethanol (20 μl/ml)
was added, and samples were boiled for 5 min. Equal
amounts of samples were separated on 12% Tris-Glycin
Polyacrylamide Gels (Invitrogen), and were then trans-
ferred to Immobilon-P membranes (Millipore). Blots
were incubated with chicken IgY antibodies derived
against various RSV Long proteins. Membranes were
incubated with a secondary antibody conjugated with
horseradish peroxidase, and blots were developed using
the ECL kit (Amersham Pharmacia Biotech).
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